Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Finished Goods (2020 - 2025)

Puma Biotechnology's Finished Goods history spans 6 years, with the latest figure at $960000.0 for Q4 2025.

  • For Q4 2025, Finished Goods rose 22.61% year-over-year to $960000.0; the TTM value through Dec 2025 reached $960000.0, up 22.61%, while the annual FY2025 figure was $960000.0, 22.61% up from the prior year.
  • Finished Goods reached $960000.0 in Q4 2025 per PBYI's latest filing, up from $439000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.6 million in Q1 2022 to a low of $186000.0 in Q4 2022.
  • Average Finished Goods over 5 years is $718823.5, with a median of $642000.0 recorded in 2022.
  • Peak YoY movement for Finished Goods: plummeted 83.9% in 2022, then surged 204.84% in 2023.
  • A 5-year view of Finished Goods shows it stood at $1.2 million in 2021, then tumbled by 83.9% to $186000.0 in 2022, then soared by 204.84% to $567000.0 in 2023, then surged by 38.1% to $783000.0 in 2024, then grew by 22.61% to $960000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Finished Goods are $960000.0 (Q4 2025), $439000.0 (Q3 2025), and $762000.0 (Q2 2025).